Premium
Conditioning with targeted busulfan for autologous peripheral blood stem cells transplantation for acute myelogenous leukemia in an XYY male
Author(s) -
Sada Eriko,
Henzan Hideho,
Ohtani Ryoko,
Takase Ken,
Miyamoto Toshihiro,
Fukuda Takahiro,
Nagafuji Koji,
Yamauchi Keita,
Takamatsu Yasushi,
Inaba Shoichi,
Harada Mine
Publication year - 2005
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.20255
Subject(s) - busulfan , medicine , etoposide , cytarabine , transplantation , leukemia , granulocyte colony stimulating factor , stem cell , acute leukemia , oncology , chronic myelogenous leukemia , hematology , chemotherapy , gastroenterology , hematopoietic stem cell transplantation , immunology , biology , genetics
We report herein a 19‐year‐old Japanese male with XYY syndrome who developed acute myelogenous leukemia. During three courses of cytotoxic chemotherapy, he suffered repeated hepatic and renal insufficiencies, possibly related to latent dysfunction from the XYY syndrome. The patient was treated with granulocyte colony‐stimulating factor combined with etoposide, cytarabine, and busulfan (the latter adjusted to a targeting dose) followed by autologous peripheral blood stem cell transplantation. He had no severe regimen‐related toxicities and is now free of leukemia. Am. J. Hematol. 78:55–58, 2005. © 2004 Wiley‐Liss, Inc.